Organisation paid for research Program year 2025 Source: CMS Open Payments

Pillar Clinical Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$9,381,771

525 payments

Through program year 2025, Pillar Clinical Research, LLC is reported as receiving $9,381,771 in research payments, across 525 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$3,543,210	14
2024	Research	$662,250	9
2023	Research	$6,500	1
2022	Research	$1,747,969	47
2021	Research	$1,018,101	161
2020	Research	$2,248,171	244
2019	Research	$155,569	49

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $4,194,418 22 payments
Sunovion Pharmaceuticals Inc. $3,711,744 294 payments
Merck Sharp & Dohme Corporation $615,478 9 payments
Corcept Therapeutics $450,332 131 payments
GW Research Limited $160,253 42 payments
Avanir Pharmaceuticals, Inc. $126,219 17 payments
Alkermes, Inc. $105,660 3 payments
Novartis Pharmaceuticals Corporation $17,543 2 payments
Boehringer Ingelheim International GmbH $125 5 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $1,983,734 1 payment
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia $1,625,066 76 payments
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia $1,097,973 27 payments
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $994,658 4 payments
A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia $610,015 6 payments
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard $561,897 4 payments
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) $552,434 3 payments
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. $250,300 113 payments
Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1) $242,694 2 payments
Cort118335-877 $239,694 60 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.